IMPA1 and diffuse large B-cell lymphoma: MiR‐381 increases the sensitivity of DLBCL to both doxorubicin and rituximab and may sensitize DLBCL to chemotherapy and targeted drugs through the downregulation of inositol monophosphatase 1 and phosphoinositide 3‐ kinase catalytic subunit delta (PI3KCD) (Table 2).6